Pfizer’s Cambridge site is a state-of-the-art R&D hub located in Kendall Square, the densest biomedical community in the world. Opened in 2014, the facility brings together nearly 1,000 colleagues who are focused on translating scientific knowledge into potential medical breakthroughs. This is taking place across areas of unmet need such as atopic dermatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), inflammatory bowel disease, muscular dystrophy, and alopecia.